Owlet, Inc. (OWLT) Appoints Marc Stoll to its Board

Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), a pioneer of smart baby monitoring, today announces the appointment of Marc Stoll to the Company’s Board of Directors. Stoll is currently an Investment Partner at Eclipse, a strategic investment firm focused on advancing the Industrial Evolution. His experience spans more than 25 years across the global finance and technology industries, and his expertise in leading corporate strategy and operational excellence will help bolster Owlet’s future ventures and growth potential.

"I’m thrilled to join Owlet’s Board of Directors after spending time becoming very familiar with the brand and products, its life-changing mission and amazing customers, and the company’s incredible team across the globe,” said Marc Stoll. “The entire Owlet community is strong, and I look forward to helping guide this company in its next chapter of advancement in medical grade, at-home infant health monitoring.”

Prior to Eclipse, Stoll was President and COO at Nextiva and has more than two decades of experience combining his financial and technology expertise derived from time as CFO at Anaplan and as Vice President of Worldwide Sales Finance at Apple. Stoll also served as Corporate Controller at CA, Inc. and as Head of Technology Equity Research at Julius Baer Investment Management. He has served on the public boards of Arista Networks, Earthlink and Windstream, and on private boards as an investor and advisor.

Owlet values Stoll’s strong operational, financial, and consumer experience in order to accelerate the Company’s global growth strategies in its consumer and medical product distribution channels. Stoll’s personal experience with remote patient monitoring and his passion for life-impacting health technologies make him a valuable addition to Owlet’s Board.

"I’ve had the pleasure of working with Marc during the recent months, and I believe his appointment to Owlet’s Board of Directors will help us continue on our growth trajectory,” said Kurt Workman, Owlet CEO and Co-Founder. “Marc, as a part of Eclipse, has proven himself to be a beneficial resource with his operational and consumer product experience. Now, as a Board member, I see him working closely with our current directors to help facilitate our progress with go-to-market strategy for our first FDA-cleared pulse-oximetry medical device, BabySat™, and future product developments. I’m excited to continue our work together and see the value Marc will add to our Board.”

Stoll will be the replacement designee of Eclipse, which maintains the right to designate up to two directors as a result of the Company’s February 2023 preferred stock financing, replacing Jayson Knafel who resigned from Owlet’s Board and stepped away as a Partner of Eclipse into a full-time CFO role.

You May Also Be Interested In

• FDA approves Novartis Pluvicto for earlier-stage prostate cancer
• INmune Bio forms advisory board for CORDStrom cell therapy platform
• Qualcomm files to resell 17.8M shares tied to Modular acquisition